At Redwood Neuro, we are detecting Alzheimer’s at its earliest stage and thereby revolutionizing treatment of this devastating disease. Imagine a world where a simple blood test has the power to detect Alzheimer's disease a staggering 15 years before symptoms appear.
At Redwood Neuro, we are turning this imagination into reality through our groundbreaking assay technology. Alzheimer’s will no longer be a specter lurking in the future but a condition we can address proactively.
Revolutionary Technology: Enables Early Diagnosis with Unparalleled Sensitivity & Reliability
What sets Redwood Neuro apart is our unique assay principle and detection technology that detects biomarkers unmeasured by other technologies.
With a sensitivity 100,000 fold greater than ELISA (the gold standard), we enable clinicians to delve deeper into the complexities of Alzheimer's disease, gaining valuable insights into its progression, mechanisms, and potential treatment approaches.
Democratizing access to ultrasensitive early-stage disease detection
Scientific studies have shown that Alzheimer’s disease biomarkers can be detected in blood years before symptoms manifest with 95% accuracy . However, the presence of the blood-brain barrier, means that these biomarkers in blood are present at very low concentrations beyond the limit of existing diagnostic technologies.
At Redwood, our technology is democratizing access to ultrasensitive early-stage disease detection.
Igniting Hope in
Alzheimer's Care
With Redwood Neuro, we have the tools to redefine what's possible in Alzheimer's care.
Alzheimer's disease progresses silently for years until symptoms appear, at which point it is often too late. Redwood Neuro's attomolar technology, however, allows the identification of disease biomarkers even at incredibly minute concentrations, creating a crucial opportunity for intervention and treatment.
By intervening at this pivotal stage, we aim to potentially delay or even avert the emergence of debilitating symptoms, paving the way for enhanced patient outcomes and a promising future in Alzheimer's care.
When we emphasize the democratization of accurate Alzheimer’s Disease detection and diagnosis, we mean it!
Our technology ensures reliable results, minimizing variability and guaranteeing reproducibility. Crucial for accurate diagnosis, research, and clinical decision-making.
Our assay technology offers a simplified workflow, minimizing the need for complicated instrumentation or technical expertise. This user-friendly approach makes it accessible to a wide range of users, including clinicians and researchers.
Our technology is biomarker agnostic, detecting over 96 biomarkers. This versatility empowers researchers and clinicians to explore diverse disease indications and customize their assays accordingly.
Our assay technology is deployable at the point-of-care, offering swift on-site diagnostics. This allows for timely interventions, enhances patient care, and supports decentralized testing.
We have achieved unprecedented levels of sensitivity and reliability, surpassing the limitations of traditional diagnostic methods. With this unrivaled sensitivity, we empower clinicians to detect the earliest signs of Alzheimer's, leading to timely interventions and optimized treatment strategies.
Redwood Surpasses Competitors with Precision & Early Detection
Our blood test achieves what is considered unattainable in medical diagnostics: broad dynamic range, high sensitivity, and low-cost
Redwood's Innovative Leap
Our instrument overcomes the complexity vs sensitivity trade-off
_
ONE ASSAY
unparalled performance
Low cost
9-log Dynamic Range
High Sensitivity
Small Form Factor
Quantitative Detection
High-throughput
A new age for early disease detection and advancements in diagnostic precision
Our ability to identify biomarkers across a broad prevalence spectrum not only empowers clinicians for early diagnosis but will also facilitate identification of the disease's stage/maturity which will change the face of patient care and treatment truly setting us apart from our competitors.
Redwood's attomolar sensitivity represents a significant advancement in medical diagnostics, offering early detection, improved accuracy, and precise disease management.
Observing subtle biomarker fluctuations and their quantities, as a result of our unparalleled dynamic range, provides key insight into disease progression and success of treatment on the patient.
There is no silver bullet in the diagnosis of Alzheimer’s and as a result our ability to detect multiple biomarkers simultaneously aids a conclusive diagnosis. However, this in of itself is not what sets us apart. Our dynamic range enables our multiplexing to be unlike any other in its ability to detect not only low concentrations of biomarkers but capturing their change and quantification over time which is crucial to an accurate diagnosis of the stage of the disease.
Low instrument cost and low per-test expense expands market reach while maintaining profitability.
Redwood's scalable solution for central labs and point-of-care customers, overcomes the complexities of traditional methods like mass spectrometry and single-molecule counting.
Redwood's Unmatched Biomarker Capabilities
Redwood’s disruptive technology enables detection of ultra-low abundance viral disease biomarkers, even at attomolar levels, outperforming market-leading instruments.
The most exciting aspect is that these capabilities have been validated through the utilization of actual patient samples, meaning the prospect of Alzheimer’s detection with increased accuracy many years before symptoms manifest is on the horizon.
Medical professionals, email us at:
professionals@redwood-neuro.com for next-gen testing solutions.
For you or a loved one, Redwood Neuro is here. Email us at:
info@redwood-neuro.com